Duloxetine medication helps reduce peripheral neuropathy pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the antidepressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a new study.

"Approximately 20% to 40% of patients with cancer who receive neurotoxic chemotherapy (eg, taxanes, platinums, vinca alkaloids, bortezomib) will develop painful chemotherapy-induced peripheral neuropathy. Painful chemotherapy-induced neuropathy can persist from months to years beyond chemotherapy completion, causing significant challenges for cancer survivors due to its negative influence on function and quality of life. Chemotherapy-induced peripheral neuropathy is difficult to manage, and most randomized controlled trials testing a variety of drugs with diverse mechanisms of action revealed no effective treatment," stated the background information in the article.

Evidence indicates that serotonin and norepinephrine dual reuptake inhibitors are effective in treating neuropathy-related pain. Several phase 3 studies have shown that duloxetine is an effective treatment for painful diabetic neuropathy.

Ellen M. Lavoie Smith, PhD, of the University of Michigan School of Nursing, Ann Arbor, and colleagues conducted a randomized phase 3 trial to examine whether duloxetine would lessen chemotherapy-induced peripheral neuropathic pain. The study included 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have a pain score of at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain after treatment with paclitaxel, another taxane, or oxaliplatin.

The initial treatment consisted of taking one capsule daily of either 30 mg of duloxetine or placebo for the first week and two capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks.

The researchers found that at the end of the initial treatment period, patients in the duloxetine-first group reported a greater reduction in average pain (average score change, 1.06) than those in the placebo-first group (average score change, 0.34). The observed average difference in the average pain score between the duloxetine-first and placebo-first groups was 0.73. Of the patients treated with duloxetine first, 59% reported any decrease in pain versus 38% of patients treated with placebo first. No change in pain was reported by 30% of duloxetine-treated patients, while 10% reported increased pain.

The authors noted that the results suggested that patients who received platinums (oxaliplatin) may have experienced more benefit from duloxetine than those who received taxanes.

Pain-related quality-of-life improved to a greater degree for those treated with duloxetine during the initial treatment than for those treated with placebo.

"In conclusion, 5 weeks of duloxetine treatment was associated with a statistically and clinically significant improvement in pain compared with placebo. Exploratory analyses raise the possibility that duloxetine may work better for oxaliplatin-induced rather than taxane-induced painful chemotherapy-induced peripheral neuropathy," the researchers wrote. This study was published April 3 in JAMA (2013; doi:10.1001/jama.2013.2813).

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs